(Curcumin + doxorubicin) is under clinical development by Immix BioPharma and currently in Phase II for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase II drugs for Triple-Negative Breast Cancer (TNBC) have a 24% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how (Curcumin + doxorubicin)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Curcumin + doxorubicin) overview

Imx-110 is under development for the treatment of chemo-resistant colon cancer, prostate cancer, esophageal  cancer, nasopharyngeal  cancer, soft tissue sarcoma, leiomyosarcoma, cholangiocarcinoma, carcinosarcoma, poorly differentiated sarcoma, triple negative breast cancer, ovarian, pancreatic cancers, malignant glioma, metastatic colorectal cancer, glioblastoma multiforme, multiple myeloma, colorectal cancer and solid tumor. Imx-110 is a first-in-class combination therapeutic candidate, that contains curcumin combined with a small amount of doxorubicin, encased in a nano-sized delivery system for optimal tumor penetration. Doxorubicin acts by targeting DNA topoisomerase II and curcumin is a signal transducer and activator of transcription 3 (Stat3), nuclear factor Kappa B (NF-kB) and poly-tyrosine kinase inhibitor (TKI).

Immix BioPharma overview

Immix BioPharma is a clinical-stage biopharmaceutical company that develops novel tissue-specific therapeutics (TSTx) in oncology and inflammation. It drugs are developed by using the SMARxT Tissue-Specific Platform. The company’s pipeline products include IMX-110, IMX-111 and IMX-120. Its IMX-110 is a negatively charged TSTx that simultaneously disables resistance pathways with a poly-kinase inhibitor and treats soft tissue sarcoma and solid tumors; IMX-111 is an apoptosis inducer for colorectal cancer and IMX-120 is a GLUT1 antibody biomarker coupled with polyphenol poly-kinase inhibitors targets inflammatory bowel diseases. In addition, the company through its subsidiaries which develops NXC-201 by using N-GENIUS cell therapy platform. The Immix BioPharma is headquartered in Los Angeles, California, the US.

For a complete picture of (Curcumin + doxorubicin)’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.